Colgate Palmolive India Names Kenvue’s India Head As New CEO

Kimberly-Clark seeks EU approval for its $40bn acquisition of Kenvue, aiming to create a consumer health and personal care giant with $32bn annual revenue. The deal, announced last November, targets $2.1bn in annual cost savings. EU regulators will assess competition concerns, with a decision pending. The acquisition would expand Kimberly-Clark's portfolio to include brands like Tylenol, Listerine, and Neutrogena.

Kimberly-Clark (KMB) has requested EU approval for its $40 billion acquisition of Kenvue, the maker of Tylenol. The deal, announced in November 2023, is expected to close in the second half of 2026. Kimberly-Clark anticipates $2.1 billion in annual cost savings and $32 billion in combined annual revenues, including Kenvue's brands like Listerine, Aveeno, and Neutrogena.

Kimberly-Clark (KMB) seeks EU antitrust approval for its $49B acquisition of Kenvue (KVUE), with a provisional deadline set for Sept. 29. The deal, approved by shareholders in January, still faces regulatory reviews in several jurisdictions, including China's Phase 2 examination. The companies aim to complete the transaction in Q4 2026, subject to approvals.

Essity's $284M acquisition of Kenvue's feminine-care business, including brands like Carefree and o.b., is under review by Brazil's competition authority. The deal is subject to regulatory approval.

Kenvue (KVUE) launched Zyrtec Allergen Shield Spray, a drug-free nasal mist that blocks allergens. The product extends Zyrtec's offerings beyond antihistamines, reflecting Kenvue's focus on proactive, drug-free allergy management. Kenvue projects $16.7B revenue and $2.3B earnings by 2029, aligning with its current valuation. The company recently increased its dividend to $0.21 per share, emphasizing shareholder returns while managing integration and restructuring efforts.

New Zealand approved Kimberly-Clark's acquisition of Kenvue, requiring the divestment of Kenvue's feminine hygiene brands (Carefree, Stayfree) in NZ and Australia. The move aims to prevent market concentration. Kimberly-Clark must sell the unit to an approved buyer to complete the deal.